Anti-oxidized low-density lipoprotein antibodies in chronic heart failure

Gideon Charach, Alexander Rabinovich, Ori Argov, Moshe Weintraub, Lior Charach, Oded Ayzenberg, Jacob George

Abstract

Oxidative stress may play a significant role in the pathogenesis of heart failure (HF). Antibodies to oxidized low-density lipoprotein (oxLDL Abs) reflect an immune response to LDL over a prolonged period and may represent long-term oxidative stress in HF. The oxLDL plasma level is a useful predictor of mortality in HF patients, and measurement of the oxLDL Abs level may allow better management of those patients. Antibodies to oxLDL also significantly correlate with the New York Heart Association score. Hypercholesterolemia, smoking, hypertension, and obesity are risk factors for atherosclerotic coronary heart disease (CHD) leading to HF, but these factors account for only one-half of all cases, and understanding of the pathologic process underlying HF remains incomplete. Nutrients with antioxidant properties can reduce the susceptibility of LDL to oxidation. Antioxidant therapy may be an adjunct to lipid-lowering, angiotensin converting enzyme inhibition and metformin (in diabetes) therapy for the greatest impact on CHD and HF. Observational data suggest a protective effect of antioxidant supplemen-
cies (ROS) and the ability to oppose/scavenge and subsequently neutralize the byproducts of these reactive free radicals\[4,13\]. Thus ROS react with NO in the setting of decreased antioxidant defenses that would normally neutralize these radicals, culminating in attenuated endothelium-dependent vasodilation in patients with HF\[2,3,8\].

Several lines of evidence suggested that oxidative stress could be involved in the pathogenesis of HF. Free radicals also have a pathogenetic role in the progressive deterioration of the degenerating myocardium\[2,4\]. Infusion of oxidized free radicals produces a marked decrease in myocardial contractility\[4,7,10\]. Immunoglobulins (Ig) to oxidized low-density lipoprotein (oxLDL) were discovered by chance by Beaumont\[9\] in a patient with multiple myeloma and hyperlipidemia. Antibodies (Abs) against oxLDL were found in many diseases other than atherosclerosis, among them HF, diabetes mellitus, renovascular syndrome, uremia, rheumatic fever, ankylosing spondylitis and lupus erythematosus\[13,14,15\]. Moreover, antibody levels of oxLDL Abs were reported to correlate significantly with the clinical status of HF patients, as defined by their New York Heart Association (NYHA) score\[8\]. Measurements of oxLDL Abs also reflect the status of lipoprotein oxidation over a prolonged period\[14\].

Assessment of oxidative stress in humans is complex since there is no reproducible, standardized methodology\[7,10,13\]. The aim of this review is to acquaint the reader with the recent research on oxLDL Abs and their use and determination in clinical practice. We also cite current studies on antioxidants and review their implications in the treatment in HF from the view that these antioxidants may contribute to longevity\[14-17\].

**PATHOPHYSIOLOGY OF LDL OXIDATION**

Oxidation of LDL is a complex process taking place in both the extra- and intracellular space\[1,3,10-13\]. It plays an important role in endothelial dysfunction as follows. Modification of LDL particles due to oxidation, glycation and binding of advanced glycation end-products (AGEs) or malondialdehyde (MDA, a final product of lipid peroxidation) is considered as being highly important in the process of atherogenesis\[4-7\]. Oxidatively modified LDL particles are distinguished by another receptor type, which was discovered on the surface of modified LDL particles are distinguished by another receptor type, which was discovered on the surface of modified LDL particles\[2,3,6-10\]. Moreover, antibody levels of oxLDL Abs were reported to correlate significantly with the clinical status of HF patients, as defined by their New York Heart Association (NYHA) score\[8\]. Measurements of oxLDL Abs also reflect the status of lipoprotein oxidation over a prolonged period\[14\].

Assessment of oxidative stress in humans is complex since there is no reproducible, standardized methodology\[7,10,13\]. The aim of this review is to acquaint the reader with the recent research on oxLDL Abs and their use and determination in clinical practice. We also cite current studies on antioxidants and review their implications in the treatment in HF from the view that these antioxidants may contribute to longevity\[14-17\].

CARDIOVASCULAR DISEASE: ANIMAL STUDIES

Experimental studies in animal models of cardiac dysfunction, such as those produced by myocardial infarction after left anterior descending artery ligation, doxorubicin administration and pressure overload, all exhibited increased production of free radicals\[16-24\]. Animal studies have addressed the potential importance of the generation of intracellular ROS in the cells that normally comprise the vessel wall. Superoxide anion \(\mathbf{O}_2^-\) was increased in the aortas of rabbits who were fed high cholesterol diets for a period of several weeks, leading to impaired endothelial-dependent relaxation that was reversible by treatment with polyethylene-glycolated superoxide dismutase or probucol\[2,19\]. Antioxidant therapy was shown to attenuate myocardial damage induced by doxorubicin\[19-21\]. Increased expression of the antioxidative superoxide dismutase gene has been reported in rats without HF after endurance training that resulted in greater NO activity\[19,20,23\].

Depressed vascular endothelial function occurred in experimental HF in rats despite an increase in endothelial NO synthetase (\(\mathbf{eNOS}\)) gene expression, and was attributed to increased vascular \(\mathbf{O}_2^-\) production\[17,20\]. Dhalla et al\[7\] suggested that the mechanism by which oxidative stress is increased by hyperlipidemia could involve the renin-angiotensin system. Both endothelial dysfunction and lesion area were improved by treatment with an angiotensin II receptor antagonist in a rabbit model\[20\]. Moreover, nicotinamide adenine dinucleotide phosphate oxidase subunit expression and \(\mathbf{O}_2^-\) production doubled in rats made hypertensive by angiotensin II infusion\[22\]. Because LDl upregulates angiotensin II receptor type 1 (AT1) expression\[9\], the effects of angiotensin II can be exacerbated by hypercholesterolemia. Finally, angiotensin II causes hypertrophy of vascular smooth muscle in a ROS-dependent fashion, a process which can participate in arterial thickening\[17,20\].

CARDIOVASCULAR DISEASE: HUMAN STUDIES, ATHEROSCLEROSIS

Atherosclerosis is the main cause of HF and the most
frequent cause of death in developed countries. Cholesterol itself is neither toxic nor antigenic towards the LDL particles that transport cholesterol; they become harmful for the organism if they are altered. It is this modification due to oxidation, glycation and binding of AGEs or MDA, which is considered most important in the process of atherosclerosis. The interaction of modified LDLs with scavenger receptors on the surface of the endothelium represents the first phase of the atherosclerotic process. Lipid peroxidation can be observed in vitro as a change in the lag phase of LDL oxidation stimulated by Cu\(^{2+}\) ions\(^{2,4,15-18}\). In vivo lipid peroxidation was especially apparent in tissue macrophages, endothelial cells and smooth muscle cells, and hemoglobin, hypochlorous acid, ceruloplasmin, lipoygenase and peroxidase appeared to be effective oxidants\(^{3,4,12}\).

**ANTI-OXLDL ABS - PREDICTOR OF MORBIDITY AND MORTALITY IN CORONARY ARTERY DISEASE**

Oxidized LDL is present in atheromatous plaques and correlates with the extent of atherosclerosis\(^{4,6,12,17,20,22-24}\). Assessment of oxLDL Abs may more reliably reflect the level of oxidative stress than plasma oxLDL. These Abs have already been shown to correlate with the extent of atherosclerosis and predict future myocardial infarction\(^{12,14-17,19-24}\). Elevated levels of Abs against oxLDL were found in many investigations to be predictive of myocardial infarction\(^{8,11,12,25-28}\). The correlation was independent of LDL cholesterol levels, though oxLDL Abs had an additive predictive effect. The mean Ab level, as expressed in optical density units, was significantly higher in cases of myocardial infarction than in controls (0.412 vs 0.356, \(P = 0.002\)). After adjustment for age, smoking, blood pressure, and HDL cholesterol levels, there was a 2.5-fold increased risk (95% confidence interval, 1.3-4.9) of a cardiac endpoint in the highest tertile of Ab level compared to the lowest tertile (\(P = 0.005\) for trend)\(^{19}\). Thus, elevated Ab levels added to the predictive effects of classic coronary risk factors\(^{5,15-17}\).

**MYOCARDIAL INSULIN RESISTANCE**

Recent human studies strongly support a link between insulin resistance and non-ischemic HF\(^{28}\). The occurrence of a specific insulin-resistant cardiomyopathy, independent of vascular abnormalities, is now recognized. Cardiac insulin resistance is characterized by reduced availability of sarcolemmal Glut4 transporters and consequent lower glucose uptake. A shift away from glycolysis towards fatty acid oxidation for adenosine triphosphate supply is apparent and is associated with myocardial oxidative stress.

The pathophysiology of cardiovascular disease in diabetes involves traditional and novel cardiac risk factors, including hypertension, dyslipidemia, smoking, genetic factors, hyperglycemia, insulin resistance/hyperinsulinemia, metabolic abnormalities, oxidative/glycative stress, inflammation, endothelial dysfunction, a procoagulant state and myocardial fibrosis. Specific vascular, myopathic and neuropathic alterations have been suggested to be responsible for the excessive cardiovascular events and mortality in diabetes\(^{25}\). These alterations manifest themselves clinically as coronary heart disease (CHD) and HF. In order to contain the emerging epidemic of cardiovascular disease, diabetic patients should have excellent glycemic control, a low normal blood pressure and low levels of LDL cholesterol, and be taking an angiotensin-converting enzyme inhibitor and aspirin, which may prevent cardiovascular disease\(^{25}\).

Metformin stimulates production of endothelial NOS, increases plasma NO levels, and improves myocardial insulin resistance.

**HF**

Tsutsui et al\(^{29}\) measured the plasma level of oxLDL by sandwich enzyme-linked immunosorbent assay with a specific monoclonal antibody against oxLDL, and showed that plasma levels of oxLDL had a good correlation with HF severity and mortality. In that study, the plasma oxLDL level was significantly higher in patients with severe HF than in patients with mild HF and healthy subjects. Others found a significant negative correlation between the plasma level of oxLDL and left ventricular ejection fraction (LVEF), and a significant positive correlation between the oxLDL plasma level and circulating norepinephrine levels\(^{16,24}\). In another study most patients (mean age 71.5 years) had systolic HF, with mean NYHA functional class of 2.7 and mean LVEF of 39.7%. Mean IgG oxLDL Abs levels in patients with hospital admissions were 3.4 times higher than those in subjects not hospitalized over the previous year\(^{15}\). Assessments of oxLDL IgG levels were able to discriminate between patients with clinically controlled HF and patients requiring hospital admission\(^{12,18,19}\).

Levels of oxLDL Abs also correlated with the presence of chronic atrial fibrillation, a finding that could be related to more severe HF or to the possible involvement of oxidative stress in the pathogenesis of atrial fibrillation\(^{15,12,15}\).

**Anti-oxLDL Abs and B-type natriuretic peptide**

Several studies found that the discriminative power of anti-oxLDL Abs was even better than that obtained for serum n-terminal pro-B-type natriuretic peptide (Nt pro-BNP) in patients admitted for worsening HF\(^{8,24,26,27}\). These results support the observation of elevated oxidative stress in patients with HF. Importantly, no association was found between Nt pro-B-type and anti-oxLDL Ab levels, suggesting that determination of the latter may have an incremental value over that provided by the former\(^{8}\). Plasma levels of oxLDL Abs were shown in many investigations to be increased with the severity of
HF in patients with different etiologies, e.g., systolic, diastolic, ischemic and valvular diseases. BNP is an established surrogate follow-up marker for patients with CHF. The results of a study by our group demonstrated that NT pro-BNP plasma levels, oxLDL Abs, LVEF and NYHA class were of prognostic value in terms of outcome in HF patients as assessed by multivariate analysis. However NT pro-BNP was a better predictor of all-cause mortality, and oxLDL. Abs plasma levels were a significant independent predictor of long-term morbidity and mortality in HF.

Abs to oxLDL significantly correlated with the mean NYHA score. The apparent differential predictive power of oxLDL. Abs and NT pro-BNP may be attributable to the different mechanisms leading to their elevated levels. Thus, NTpro-BNP represents the neurohormonal axis, whereas oxLDL. Abs mirror oxidative stress. These two mechanisms governing HF progression can predict different endpoints in the management of patients with HF.

**CLINICAL IMPACT OF OXLDL ON REHABILITATION AND PROGNOSIS**

Oxidized LDL Abs could prove to be a useful marker for predicting the clinical course and outcome of many patients with HF of different etiologies. There is an urgent need to develop simplified assays that are applicable for high-throughput analysis. The patient's oxidant status can be assessed and the true efficacy of antioxidant therapies can then be established so that effective therapy can be provided selectively. Refinement of clinical trial designs to incorporate such indices would ensure recruitment of appropriate patients, identify the most efficient antioxidant dosing regimens and perform controlled analysis. Better monitoring and prognostic predictors are required in order to achieve further improvement in the management of patients with HF.

Vascular endothelial function and, particularly, NO-mediated vasodilation are clearly enhanced by physical training among HF patients. The molecular basis for this improvement is unclear, although animal studies support either of two (nonexclusive) mechanisms. One attractive hypothesis is that training induces NO production by increased expression of the gene encoding eNOS. The NOS promoter contains a cis-acting shear-stress response element, and so its expression could be regulated directly by periodic increases in blood flow that occur during physical training. Alternatively, vasodilation could be enhanced indirectly after training by a distinct mechanism that decreases oxygen free radicals that otherwise can inactivate NO.

Rehabilitation programs involving immersed exercises are more and more frequently recommended for even severe cardiac patients. Laurent et al studied one group of 24 male stable CHF patients and 24 male coronary artery disease (CAD) patients with preserved left ventricular function who participated in a rehabilitation program performing cycle endurance exercises on land. They also performed gymnastic exercises either on land (first half of the participants) or in water (second half). Resting plasma concentration of NO metabolites (nitrates and nitrates) and catecholamines were evaluated, and a symptom-limited exercise test on a cycle ergometer was performed before and after the rehabilitation program. The plasma concentration of nitrates in the groups that performed water-based exercises was significantly increased (P = 0.035 for CHF and P = 0.042 for CAD), whereas it did not significantly change in the groups that performed gymnastic exercise on land. Plasma catecholamine concentration levels did not change but the cardiorespiratory capacity of all patients was significantly increased after rehabilitation. The water-based exercises seemed to effectively increase the basal level of plasma nitrates. Such changes may be related to an enhancement of endothelial function and may be of importance for the patient's overall health status.

**ANTIOXIDANTS**

As mentioned earlier, free radicals have a role in the progressive deterioration of the decompensating myocardium. Antioxidants terminate these chain reactions by removing free radical intermediates and inhibiting other oxidation reactions. They do this by being oxidized themselves, therefore antioxidants, e.g., thiols, ascorbic acid, or polyphenols, often act as reducing agents. Overall, these low molecular mass antioxidant molecules add significantly to the defense provided by the enzymes superoxide dismutase, catalase and glutathione peroxidase. However, antioxidant vitamin therapy has not been convincingly demonstrated in randomized trials as being beneficial. The data are, however, entirely consistent with the alternative hypothesis, that reduced oxidative stress may account for the increase in vascular NO-mediated vasodilation. An insight into the mechanism of this process may be relevant when considering therapies for exercise-intolerant HF patients. A critical review of the role of dietary antioxidants suggested that vitamins A and E along with coenzyme Q10, flavonoids, and resveratrol show promise in extending human life. That review examined current studies on antioxidants and their implications in the aging process, with the conclusion that these antioxidants may contribute to longevity.

However, the possibility of translating the patient's oxidant status into use of effective antioxidant drugs is not supported by current evidence. Notwithstanding promising observational data, prospective, double-blind, placebo-controlled trials did not support a causal relationship between antioxidant therapy, mainly vitamin supplements, and lowering of CAD risk.

We reviewed recently published basic research on the protective cardiovascular effects of antioxidants, especially resveratrol, because they may lead to the development of new treatment in patients with HF. Vitamin A has been called the “anti-infective” vitamin because of its role in supporting the immune system. Carotenoids,
which are pre-formed vitamin A found in plants, turned out to be determinants of longevity.[40] Vitamin A supplementation led to an improvement in the lifespan of mice only when its use was initiated at the beginning of life.[40] One of the most widely researched antioxidants, vitamin E, was similarly found to extend life in mice when initiated in the early years. Vitamin E may protect older healthy individuals against atherosclerosis (formation of thick plaque of cholesterol and other lipids in arterial walls), improve relearning ability, and reduce cancer formation.[39]. However, vitamin E supplementation might be associated with an increase in total mortality, HF, and hemorrhagic stroke[38]. Vitamin E has been shown to increase oxidative resistance \textit{in vitro} and prevent atherosclerotic plaque formation in mouse models.[40] Consumption of foods rich in vitamin E has been associated with a lower risk of CHD in middle-aged to older men and women.[39]. However clinical studies have not demonstrated a benefit of vitamin E in the primary and secondary prevention of cardiovascular disease.[38]. The American Heart Association does not support the use of vitamin E supplements to prevent cardiovascular disease, but it does recommend the consumption of foods abundant in antioxidant vitamins and other nutrients.[35,47].

Coenzyme Q10 is the only known antioxidant synthesized in the body.[40]. It extends life by reducing oxidative damage, thereby lowering cardiovascular risk and inflammation. The Q10 is the primary homologue found in longer-living mammalian species, including human beings. There were non-significant trends towards increased LVEF and reduced mortality in nine randomized trials of Q10 in HF published up to 2003.[40]. Q10 decreases proinflammatory cytokines and decreases blood viscosity, which is helpful in patients with HF and CAD. It also improves ischemia and reperfusion injury of coronary revascularization. Q10 decreases proinflammatory cytokines and decreases blood viscosity, which is helpful in patients with HF and CAD. It also improves ischemia and reperfusion injury of coronary revascularization.[48]. It was recently found to be an independent predictor of mortality in congestive HF. Coenzyme Q10 has also been found to be helpful in vertigo and Meniere-like syndrome by improving the immune system.[48]. There is ongoing research aimed at firmly establishing its role in the treatment of cardiovascular diseases.[40].

Flavonoids are the most common group of polyphenolic compounds in the human diet and are found mostly in plants. Flavanol-rich chocolate acutely improves vascular and platelet function in patients with HF[44]. Green tea supplementation has been found to protect against oxidative stress, and it increased antioxidant ability in the rat brain[43]. Another flavonoid, anthocyanin, has also been shown to be protective against vascular disease[37,45]. Resveratrol is a polyphenolic compound found in grapes, red wine, purple grape juice, peanuts, and some berries. Evidence from the “French Paradox” and from controlled studies point to its effectiveness in extending life[57]. It has also been associated with improved bone density, motor coordination, cardiovascular function, and in delaying cataracts. Other studies also show that it offers protection against Alzheimer's disease and prolongs the human lifespan as well as retarding aging[35]. The cardiovascular protective capacities of resveratrol are associated with multiple molecular targets and this may lead to the development of novel therapeutic strategies for atherosclerosis, ischemia/reperfusion, metabolic syndrome, and HF[37].

The pleiotropic effects of statins appear to result from improvements in endothelial function, a reduction in inflammatory mediators, a decline in the development of atheroma through the stabilization of atheromatosous plaques, and the inhibition of cardiac hypertrophy through an antioxidant mechanism[35]. Long-term statin use may reduce morbidity and mortality rates in a broad range of patients.[35]. However, lower LDL cholesterol levels appear to predict a less favorable outcome in patients with HF, particularly those taking statins, raising questions about the need for an aggressive LDL-cholesterol-lowering strategy in patients with HF, regardless of its etiology[35,49]. Clopidogrel treatment in patients with CAD not only inhibits platelet activation but also improves endothelial function and NO bioavailability. HF is associated with endothelial dysfunction and increased platelet activation. Hu et al.[35] investigated whether treatment with clopidogrel modified endothelial function in HF following myocardial infarction and concluded that endothelial dysfunction and vascular oxidative stress have a positive prognostic impact on cardiovascular events.

Nitrates are very effective anti-ischemic drugs used for the treatment of patients with stable angina, acute myocardial infarction and chronic congestive HF. There are new data on the protective properties of the organic nitrate pentaerythritol tetrinitrate, which, in contrast to all other organic nitrates, is able to upregulate enzymes with a strong anti-oxidative capacity thereby preventing tolerance and the development of endothelial dysfunction.[40]. Carvedilol is a beta-blocker with antioxidant properties. In several large clinical trials on patients with mild to severe HF, treatment with carvedilol improved mortality, especially in severe cases with the worst prognosis[32,41]. The beta-blocker nebivolol has been used in Europe for almost 10 years.[42]. Like carvedilol, it belongs to the third generation of beta-blockers which possess direct vasodilator properties in addition to their adrenergic blocking characteristics.[42]. Nebivolol has the highest beta (1)-receptor affinity among the beta-blockers and, most interestingly, it substantially improves endothelial dysfunction \textit{via} its strong stimulatory effects on the activity of e-NOS and \textit{via} its antioxidative properties. Because impaired endothelial activity is considered a major causal role in the pathophysiology of congestive HF, the endothelium-agonistic properties of nebivolol suggest that this drug might provide additional benefit beyond beta-receptor blockade. Clinically, this compound has been proven to have antihypertensive and anti-ischemic effects as well as beneficial effects on hemodynamics and prognosis in
patients with chronic congestive HF. Further studies are required to compare the benefit of nebivolol in terms of its prognostic impact in patients with HF. Spironolactone is an aldosterone receptor antagonist that has been shown to decrease mortality in patients with severe HF when added to conventional therapy. Treatment with spironolactone resulted in a significant increase in the forearm blood flow response to acetylcholine. This demonstration of improvement in endothelial function (caused by oxidative stress) provides a novel mechanism for the beneficial effect of spironolactone in HF patients. Angiotensin converting enzyme inhibitors (ACEI) and angiotensin receptor blockers are widely used drugs for HF to prevent hypertrophy of the myocardium and vascular smooth muscle caused by angiotensin II in a ROS-dependent fashion, which can contribute to arterial thickening. Treatment of patients with HF, CAD and other conditions associated with endothelial dysfunction induced by oxidative stress with an ACEI (especially quinapril) has been shown to improve endothelium-dependent vasodilation and contribute to increased exercise capacity.

Some studies have shown that metformin activates AMP-activated protein kinase and has a potent cardio-protective effect against ischemia/reperfusion injury as result of oxidative stress. Both left ventricular fractional shortening and left ventricular end-diastolic pressure were significantly improved in dogs treated with oral metformin. As a result of these effects, metformin decreased apoptosis and improved cardiac function in failing canine hearts. Therefore, metformin may be a potential new therapy for HF.

CONCLUSION

The OxLDL Ab level is a useful predictor of morbidity and mortality in HF patients. Assessment of oxidative stress in humans is complex. Since there is no reproducible, standardized methodology, additional prospective data with further determination of oxLDL Ab levels may prove oxLDL Abs as a useful marker for predicting exacerbations in patients with HF.

Therapies that improve endothelial function caused by oxidative stress have been shown to improve exercise tolerance and outcomes in patients with HF. Dietary antioxidants such as vitamin A along with coenzyme Q10, flavonoids, and resveratrol, and medicines such as spironolactone, pentaerythrityl tetranitrate, nebivolol, quinaprilat, clopidogrel and metformin show promise in extending human life in patients with HF.

Further research will be needed to elucidate therapies based on this biology that could increase NO production, interrupt the pathologic cascade that results in generation of free radicals, and augment antioxidant defenses in patients with HF.

REFERENCES

1. Packer M. Survival in patients with chronic heart failure and its potential modification by drug therapy. In: Cohn JN, editor. Drug treatment of heart failure. 2nd ed. Secaucus, NJ: Advanced Therapeutics Communications International, 1988; 273
2. Winlaw D, Smythe G, Keough A, Schuyvens C, Spratt P, MacDonald P, Smythe G. Increased nitric oxide production in heart failure. Lancet 1994; 344: 373-374
3. Sharma R, Davidoff MN. Oxidative stress and endothelial dysfunction in heart failure. Con gest Heart Fail 2002; 8: 165-172
4. Griending K, FitzGerald GA. Oxidative stress and cardiovascular injury: Part II: animal and human studies. Circulation 2003; 108: 2034-2040
5. McMurray J, Chopra M, Abdullah I, Smith WE, Dargie HJ. Evidence of oxidative stress in chronic heart failure in humans. Eur Hear J 1993; 14: 1493-1498
6. Boulier A, Bird DA, Chang MK, Dennis EA, Friedman P, Giglott-Taylor K, Hörkkö S, Palinski W, Quehenberger O, Shaw P, Steinberg D, Terpstra V, Witzum JL. Scavenger receptors, oxidized LDL, and atherosclerosis. Ann N Y Acad Sci 2001; 947: 214-222; discussion 222-223
7. George J, Wester D, Bosch T, Shesps D, Keren G. Usefulness of anti-oxidized LDL antibody determination for assessment of clinical control in patients with heart failure. Eur J Heart Fail 2006; 8: 58-62
8. Charach G, George J, Afek A, Wester D, Shesps D, Keren G, Rubinstein A. Antibodies to oxidized LDL as predictors of morbidity and mortality in patients with chronic heart failure. J Card Fail 2009; 15: 770-774
9. Beaumont JL. L’hyperlipidé mie par autoanticorps anti-beta-lipoprotine. Une nouvelle entité pathologique. C R Acad Sci Paris 1965; 261: 4563-4566
10. Steinerová A, Racek J, Stozicky F, Zima T, Fialová L, Lapin A. Antibodies against oxidized LDL--theory and clinical use. Physiol Res 2001; 50: 131-141
11. Chong-Han K. Dietary lipophilic antioxidants: implications and significance in the aging process. Crit Rev Food Sci Nutr 2010; 50: 931-957
12. Ennezat PV, Malendowicz SL, Testa M, Colombo PC, Cohen-Solal A, Evans T, Lejeune TH. Physical training in patients with chronic heart failure enhances the expression of genes encoding antioxidative enzymes. J Am Coll Cardiol 2001; 38: 194-198
13. Holvoet P, Mertens A, Verhamme P, Bogaerts K, Beyens G, Verhaeghe R, Collen D, Muls E, Van de Werf F. Cirulating oxidized LDL is a useful marker for identifying patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2001; 21: 844-848
14. Holvoet P, Vanhaecke J, Janssens S, Van der Werf F, Collen D. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 1998; 98: 1487-1494
15. Myers CE, McGuire WP, Liss RH, Iffrin I, Grotzinger K, Young RC. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science 1977; 197: 165-167
16. Singal PK, Kapur N, Dhillon KS, Beamish RE, Dhalla NS. Role of free radicals in cardiovascular disease. Curr J Pharmacol 1982; 60: 1390-1397
17. Dhalla AK, Hill MF, Singal PK. Role of oxidative stress in transition of hypertrophy to heart failure. J Am Coll Cardiol 1996; 28: 506-514
18. Salonen JT, Vartiainen E, Nyyssönen K, Palinski W, Witztum JL. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 1992; 339: 883-887
19. Puurunen M, Manttari M, Manninen V, Tenkanen L, Alfant G, Ehholm C, Vaara O, Aho K, Palouso T, Antibody against oxidized low-density lipoprotein predicting myocardial infarction. Arch Intern Med 1994; 154: 2605-2609
20. Hollander J, Fiebig R, Gore M, Bejma J, Ookawara T, Ohno H, Ji LL. Superoxide dismutase gene expression in skeletal...
muscle: fiber-specific adaptation to endurance training. Am J Physiol 1999; 277: R565-R562
21 Katz SD, Yuen J, Bijou R, Lefemite TH. Training improves endothelium-dependent vasodilation in resistance vessels of patients with heart failure. J Appl Physiol 1997; 82: 1488-1492
22 Bauersachs J, Bouloumâ A, Farcarelli D, Hu K, Busse R, Ertl G. Endothelial dysfunction in chronic myocardial infarction despite increased vascular endothelial nitric oxide synthesis and soluble guanylate cyclase expression: role of enhanced vascular superoxide production. Circulation 1999; 100: 292-298
23 Tsutsui T, Tsuchimoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Ohnishi M, Kinoshita M. Plasma oxidized low-density lipoprotein as a prognostic predictor in patients with chronic congestive heart failure. J Am Coll Cardio 2002; 39: 957-962
24 Anand IS, Fisher LD, Chiang YT, Latin R, Masson S, Maggioni AP, Glazer RD, Tognoni G, Cohn JN. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in theValsartan Heart Failure Trial (Val-HeFT). Circulation 2003; 107: 1278-1283
25 Candido R, Srivastava P, Cooper ME, Burrell LM. Diabetes mellitus: a cardiovascular disease. Curr Opin Investig Drugs 2003; 4: 1088-1094
26 Hambrecht R, Fiehen E, Weigl C, Gielen S, Hamann C, Kaiser R, Yu J, Adams V, Niebauer J, Schuler G. Regular physical exercise corrects endothelial dysfunction and improves exercise capacity in patients with chronic heart failure. Circulation 1998; 98: 2709-2715
27 Hornig B, Maier V, Drexler H. Physical training improves endothelial function in patients with chronic heart failure. Circulation 1996; 93: 210-214
28 Cambi GE, Lucchese G, Djokeng MM, Modesti A, Fiaschi T, Faggian G, Sani G, Modesti PA. Impaired JAK2-induced activation of STAT3 in failing human myocytes. Mol Biosyst 2012; 8: 2351-2359
29 Koller A, Huang A, Sun D, Kaley G. Exercise training augments flow-dependent dilation in rat skeletal muscle arterioles. Role of endothelial nitric oxide and prostaglandins. Circ Res 1995; 76: 544-550
30 Sessa WC, Pritchard K, Seyerdi N, Wang J, Hintze TH. Chronic exercise in dogs increases coronary vascular nitric oxide production and endothelial cell nitric oxide synthase gene expression. Circ Res 1994; 74: 549-553
31 Varin R, Mulder P, Richard V, Tamion F, Devaux C, Henry JP, Lallemand F, Lerebours G, Thullez C. Exercise improves flow-mediated vasodilatation of skeletal muscle arteries in rats with chronic heart failure. Role of nitric oxide, prostanoids, and oxidant stress. Circulation 1999; 99: 2951-2957
32 Resnich N, Gimbrone MA. Hemodynamic forces are complex regulators of endothelial gene expression. FASEB J 1995; 9: 874-882
33 Laurent M, Daline T, Malika B, Fawzi O, Philippe V, Benoit D, Catherine M, Jacques R. Training-induced increase in nitric oxide metabolites in chronic heart failure and coronary artery disease: an extra benefit of water-based exercises? Eur J Cardiovasc Prev Rehabil 2009; 16: 215-221
34 Heiss C, Keen CL, Kelm M. Flavonols and cardiovascular disease prevention. Eur Heart J 2010; 31: 2583-2592
35 Sarem A, Arora R. Vitamin E and cardiovascular disease. Am J Ther 2010; 17: e56-e65
36 Yamagishi S, Matsui T. Nitric oxide, a Janus-faced therapeutic target for diabetic microangiopathy-Friend or foe? Pharma Col Res 2011; 41: 187-194
37 Wang H, Yang YJ, Qian HY, Zhang Q, Xu H, Li JJ. Resveratrol in cardiovascular disease: what is known from current research? Heart Fail Rev 2012; 17: 437-448
38 Marzilli M. Pleiotropic effects of statins: evidence for benefits beyond LDL-cholesterol lowering. Am J Cardiovasc Drugs 2010; 10: Suppl 1: 3-9
39 Sukumaran V, Veeraveedu PT, Gurusamy N, Yamaguchi K, Lakshmanan AP, Ma M, Suzuki K, Kodama M, Watanabe K. Cardioprotective effects of telmisartan against heart failure in rats induced by experimental autoimmune myocarditis through the modulation of angiotensin-converting enzyme-2/angiotensin 1-7 mas receptor axis. Int J Biol Sci 2011; 7: 1077-1092
40 Dailer A, Wenzel P, Oelze M, Muchel T. New insights into bioactivation of organic nitrates, nitrates tolerance and cross-tolerance. Clin Res Cardio 2008; 97: 12-20
41 Matsuda Y, Akita H, Terashima M, Shiga N, Kanazawa K, Yokoyama M. Carvedilol improves endothelium-dependent dilatation in patients with coronary artery disease. Am Heart J 2000; 140: 753-759
42 Münzel T, Corti T. Nebivolol: the somewhat-different beta-adrenergic receptor blocker. J Am Coll Cardio 2009; 54: 1491-1499
43 Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717
44 Hornig B, Arakawa N, Haussmann D, Drexler H. Differential effects of quinaprilat and enalaprilat on endothelial function of conduit arteries in patients with chronic heart failure. Circulation 1998; 98: 2842-2848
45 Flammer AJ, Sudano I, Wolfrum M, Thomas R, Enseleit F, Périat D, Kaiser P, Hirt A, Herrmann M, Serafini M, Lévéques A, Lüscher TF, Ruschitzka F, Noll G, Corti R. Cardiovascular effects of flavanol-rich chocolate in patients with heart failure. Eur Heart J 2012; 33: 2172-2180
46 Tinkel J, Hassanah H, Khouri SJ. Cardiovascular antioxidant therapy: a review of supplements, pharmacotherapies, and mechanisms. Cardiol Rev 2012; 20: 77-83
47 Pryor WA. Vitamin E and heart disease: basic science to clinical intervention trials. Free Radic Biol Med 2000; 28: 141-164
48 Kumar A, Kaur H, Devi P, Mohan V. Role of coenzyme Q10 (CoQ10) in cardiac disease, hypertension and Meniere-like syndrome. Pharmacol Ther 2009; 124: 259-268
49 Charach G, George J, Roth A, Rogowski O, Weder D, Sheps D, Grosskopf I, Weintraub M, Keren G, Rubinstein A. Baseline low-density lipoprotein cholesterol levels and outcome in patients with heart failure. Am J Cardio 2010; 105: 100-104
50 Hu H, Batteux F, Chereau C, Kavian N, Marut W, Gobeaux C, Borderie D, Dinh-Xuan AT, Weill B, Nicco C. Clopidogrel protects from cell apoptosis and oxidative damage in a mouse model of renal ischaemia-reperfusion injury. J Pathol 2011; 225: 265-275
51 Mellor KM, Bell JR, Ritchie RH, Delbridge LM. Myocardial insulin resistance, metabolic stress and autophagy in diabetes. Clin Exp Pharmacol Physiol 2012 Jul 15; Epub ahead of print
52 Sasaki H, Asanuma H, Fujita M, Takahama H, Wakeno M, Ito S, Ogai A, Asakura M, Kim J, Minamino T, Takashima S, Sanada S, Sugimachi M, Konamura K, Mochizuki N, Kita- kaze M. Meflophen prevents progression of heart failure in dogs: role of AMP-activated protein kinase. Circulation 2009; 119: 2568-2577

S-Editor Cheng JX L-Editor Cant MR E-Editor Li JY